Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Roche to name a new CEO by March 2023

<< Previous

Bullboard Posts

Next >>

Comment by itntdfon Feb 08, 2023 3:03pm

105 Views

Post# 35275264

RE:RE:RE:RE:RE:RE:RE:RE:Roche to name a new CEO by March 2023

exactly how does it seem plausible that AN would walk away from any use of pela when it purchased those rights for $80k, milestone payments, and the payment of double digit royalties for a population making up nearly 20% of the world's total?

oh yeah, right. they'll just give up potentiall billions of dollars in sales to make things easier for big pharma to take out oncy and then leave AN in the cold.

what do you think is plausible regarding the warrants to purchase oncy capital stock that AN was given in their agreement with oncy?

<< Previous

Bullboard Posts

Next >>

Mid-year review: How has gold been performing?